Trace amine-associated receptor 1 (TAAR1) agonism as a new treatment strategy for schizophrenia and related disorders
EF Halff, G Rutigliano, A Garcia-Hidalgo… - Trends in …, 2023 - cell.com
Schizophrenia remains a major health burden, highlighting the need for new treatment
approaches. We consider the potential for targeting the trace amine (TA) system. We first …
approaches. We consider the potential for targeting the trace amine (TA) system. We first …
Therapeutic potential of TAAR1 agonists in schizophrenia: evidence from preclinical models and clinical studies
Trace amine-associated receptor 1 (TAAR1) has emerged as a promising therapeutic target
for neuropsychiatric disorders due to its ability to modulate monoaminergic and …
for neuropsychiatric disorders due to its ability to modulate monoaminergic and …
[HTML][HTML] Pharmacology of human trace amine-associated receptors: Therapeutic opportunities and challenges
The discovery in 2001 of a G protein-coupled receptor family, subsequently termed trace
amine-associated receptors (TAAR), triggered a resurgence of interest in so-called trace …
amine-associated receptors (TAAR), triggered a resurgence of interest in so-called trace …
Ulotaront: a TAAR1 agonist for the treatment of schizophrenia
Ulotaront (SEP-363856) is a trace-amine associated receptor 1 (TAAR1) agonist with 5-
HT1A receptor agonist activity in Phase 3 clinical development, with FDA Breakthrough …
HT1A receptor agonist activity in Phase 3 clinical development, with FDA Breakthrough …
The case for TAAR1 as a modulator of central nervous system function
G Rutigliano, A Accorroni, R Zucchi - Frontiers in pharmacology, 2018 - frontiersin.org
TAAR1 is widely expressed across the mammalian brain, particularly in limbic and
monoaminergic areas, allegedly involved in mood, attention, memory, fear, and addiction …
monoaminergic areas, allegedly involved in mood, attention, memory, fear, and addiction …
[HTML][HTML] Negative symptoms in schizophrenia: Newly emerging measurements, pathways, and treatments
SR Marder, D Umbricht - Schizophrenia Research, 2023 - Elsevier
The negative symptoms of schizophrenia, which often appear earlier than any other
symptom, are prominent and clinically relevant in the majority of patients. As a result, interest …
symptom, are prominent and clinically relevant in the majority of patients. As a result, interest …
[HTML][HTML] Present and future antipsychotic drugs: A systematic review of the putative mechanisms of action for efficacy and a critical appraisal under a translational …
A de Bartolomeis, A Barone, V Begni, MA Riva - Pharmacological research, 2022 - Elsevier
Antipsychotics represent the mainstay of schizophrenia pharmacological therapy, and their
role has been expanded in the last years to mood disorders treatment. Although introduced …
role has been expanded in the last years to mood disorders treatment. Although introduced …
TAAR1 dependent and independent actions of the potential antipsychotic and dual TAAR1/5-HT1A receptor agonist SEP-363856
Abstract SEP-363856 (SEP-856) is a novel antipsychotic under clinical development. It
displays a unique pattern of receptor interaction, with only weak (partial agonist) activity at …
displays a unique pattern of receptor interaction, with only weak (partial agonist) activity at …
Pathological overeating: emerging evidence for a compulsivity construct
Compulsive eating behavior is a transdiagnostic construct that is characteristic of medical
and psychiatric conditions such as forms of obesity and eating disorders. Although feeding …
and psychiatric conditions such as forms of obesity and eating disorders. Although feeding …
Pronounced hyperactivity, cognitive dysfunctions, and BDNF dysregulation in dopamine transporter knock-out rats
Dopamine (DA) controls many vital physiological functions and is critically involved in
several neuropsychiatric disorders such as schizophrenia and attention deficit hyperactivity …
several neuropsychiatric disorders such as schizophrenia and attention deficit hyperactivity …